Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy

Expert Opinion on Drug Delivery

Volumn 8, Issue 1, 2011, Pages 113-126

  Su, Kai ^a   Shi, Xuetao ^a   Varshney, Rohan R ^a   Wang, Dong An ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

Bioconjugate; Bisphosphonate; Controlled release; Orthopedics

Indexed keywords

ACRYLIC CEMENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM PHOSPHATE; GADOLINIUM; GALLIUM; HYDROXYAPATITE; MCM 41; MICROSPHERE;

ASEPTIC NECROSIS; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; GASTROINTESTINAL ABSORPTION; HUMAN; OSTEOPOROSIS; REVIEW; SIDE EFFECT; TRANSPLANTATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DELAYED-ACTION PREPARATIONS; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; OSTEOPOROSIS;

EID: 78650556609     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.541438     Document Type: Review

References (100)

1. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19(6):733-59 . An excellent review of mechanisms of action of BPs.
2. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13(4):581-9
3. Grazio S, Babic-Naglic D, Kehler T, Curkovic B. Persistence of weekly alendronate: A real-world study in Croatia. Clin Rheumatol 2008;27(5):651-3
4. Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom 2003;6(1):45-50 (Pubitemid 36183115)
5. Kiagia M, Karapanagiotou E, Charpidou A, et al. Rapid infusion of ibandronate in lung cancer patients with bone metastases. Anticancer Res 2006;26(4 B):3133-6 (Pubitemid 44161812)
6. Grey A, Bolland MJ, Wattie D, et al. The antiresorptive effects of a single dose of zoledronate persist for two years: A randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009;94(2):538-44
7. Body JJ. Clinical research update: Zoledronate. Cancer 1997;80(8 Suppl):1699-701
8. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug Dev Res 2002;55(4):210-24
9. Coleman RE. Bisphosphonates in breast cancer. Annals Oncol 2005;16(5):687-95
10. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22 (Pubitemid 46698462)
11. Rauch F, Glorieux FH. Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet Semin Med Genet 2005;139C(1):31-7 (Pubitemid 41739245)
12. Borah B, Ritman EL, Dufresne TE, et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: Correlation to histomorphometric indices of turnover. Bone 2005;37(1):1-9 (Pubitemid 40848411)
13. Little DG, McDonald M, Sharpe IT, et al. Zoledronic acid improves femoral head sphericity in a rat model of perthes disease. J Orthop Res 2005;23(4):862-8 (Pubitemid 40960039)
14. Russell RGG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone 1999;25(1):97-106
15. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000;42(3):175-95 (Pubitemid 30645777)
16. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006;38(5):617-27
17. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of milligrams once weekly: A placebo-controlled endoscopy study. Am J Gastroenterol 2002;97(1):58-64 (Pubitemid 34059764)
18. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Int Med 2006;144(10):753-61
19. Josse S, Faucheux C, Soueidan A, et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005;26(14):2073-80 (Pubitemid 39575349)
20. Peter B, Gauthier O, Laib S, et al. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mater Res -Part A 2006;76(1):133-43 (Pubitemid 43075691)
21. Palazzo B, Iafisco M, Laforgia M, et al. Biomimetic hydroxyapatite-drug nanocrystals as potential bone substitutes with antitumor drug delivery properties. Adv Funct Mater 2007;17(13):2180-8 (Pubitemid 47396205)
22. Samdancioglu S, Calis S, Sumnu M, Hincal AA. Formulation and in vitro evaluation of bisphosphonate loaded microspheres for implantation in osteolysis. Drug Dev Ind Pharm 2006;32(4):473-81
23. Nafea EH, El-Massik MA, El-Khordagui LK, et al. Alendronate PLGA microspheres with high loading efficiency for dental applications. J Microencapsul 2007;24(6):525-38
24. Shi X, Wang Y, Ren L, et al. Enhancing alendronate release from a novel PLGA/ hydroxyapatite microspheric system for bone repairing applications. Pharm Res 2009;26(2):422-30
25. Sutton SC, Engle K, Fix JA. Intranasal delivery of the bisphosphonate alendronate in the rat and dog. Pharm Res 1993;10(6):924-6 (Pubitemid 23167579)
26. Duncan AR. The use of subcutaneous pamidronate. J Pain Symptom Manage 2003;26(1):592-3
27. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(Suppl 4):28-37 (Pubitemid 39363166)
28. Adami S, Zamberlan N. Adverse effects of bisphosphonates: A comparative review. Drug Saf 1996;14(3):158-70 (Pubitemid 126426313)
29. Kresge CT, Leonowicz ME, Roth WJ, et al. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 1992;359(6397):710-12
30. Inagaki S, Fukushima Y, Kuroda K. Synthesis of highly ordered mesoporous materials from a layered polysilicate. J Chem Soc Chem Commun 1993(8):680-2
31. Balas F, Manzano M, Horcajada P, Vallet-Regi M. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc 2006;128(25):8116-17 (Pubitemid 43967738)
32. Nieto A, Balas F, Colilla M, et al. Functionalization degree of SBA-15 as key factor to modulate sodium alendronate dosage. Microporous Mesoporous Mater 2008;116(1-3):4-13 . The first study showing the relationship between BP dosage and the functionalization degree of delivery matrix.
33. Nieto A, Colilla M, Balas F, Vallet-Regi M. Surface electrochemistry of mesoporous silicas as a key factor in the design of tailored delivery devices. Langmuir 2010;26(7):5038-49
34. Colilla M, Izquierdo-Barba I, Vallet-Regi M. Phosphorus-containing SBA-15 materials as bisphosphonate carriers for osteoporosis treatment. Microporous Mesoporous Mater 2010;135(1-3):51-9
35. Colilla M, Manzano M, Izquierdo-Barba I, et al. Advanced drug delivery vectors with tailored surface properties made of mesoporous binary oxides submicronic spheres. Chem Mater 2010;22(5):1821-30 . The first study introducing mesostructured binary oxides as a BP delivery system.
36. Daculsi G, Bouler JM, Legeros RZ. Adaptive crystal formation in normal and pathological calcifications in synthetic calcium phosphate and related biomaterials. Int Rev Cytol 1997;172:129-91 (Pubitemid 27149655)
37. LeGeros RZ. Calcium phosphates in oral biology and medicine. Monogr oral sci 1991;15:1-201
38. Rush SM. Bone graft substitutes: Osteobiologics. Clin Podiatr Med Surg 2005;22(4):619-30
39. Vallet-Regi M. Revisiting ceramics for medical applications. Dalton Trans 2006(44):5211-20 (Pubitemid 44707886)
40. Matsumoto T, Okazaki M, Inoue M, et al. Hydroxyapatite particles as a controlled release carrier of protein. Biomaterials 2004;25(17):3807-12 (Pubitemid 38327069)
41. Oliveira AL, Pedro AJ, Saiz Arroyo C, et al. Biomimetic Ca-P coatings incorporating bisphosphonates produced on starch-based degradable biomaterials. J Biomed Mater Res Part B Appl Biomater 2010;92(1):55-67
42. Faucheux C, Verron E, Soueidan A, et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res Part A 2009;89(1):46-56
43. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9:S66-S80 (Pubitemid 29231759)
44. Kamoi K, Yoneyama T, Nishizawa K, et al. Application of bone grafts to periodontal therapy. 1. Material and biological studies on hydroxyapatite. Nippon Shishubyo Gakkai kaishi 1984;26(2):275-88
45. Seshima H, Yoshinari M, Takemoto S, et al. Control of bisphosphonate release using hydroxyapatite granules. Journal of Biomed Mater Res Part B Appl Biomater 2006;78(2):215-21 (Pubitemid 44167721)
46. Iafisco M, Palazzo B, Marchetti M, et al. Smart delivery of antitumoral platinum complexes from biomimetic hydroxyapatite nanocrystals. J Mater Chem 2009;19(44):8385-92
47. Boanini E, Gazzano M, Rubini K, Bigi A. Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure. Adv Mater 2007;19(18):2499-502 The first paper to report a modified method of hydroxyapatite synthesis for the preparation of composite nanocrystals containing alendronate. (Pubitemid 47481802)
48. Bigi A, Boanini E, Capuccini C, et al. Biofunctional alendronate- Hydroxyapatite thin films deposited by matrix assisted pulsed laser evaporation. Biomaterials 2009;30(31):6168-77
49. Roussiere H, Fayon F, Alonso B, et al. Reaction of zoledronate with beta-tricalcium phosphate for the design of potential drug device combined systems. Chem Mater 2008;20(1):182-91 (Pubitemid 351256726)
50. Ong HT, Loo JSC, Boey FYC, et al. Exploiting the high-affinity phosphonate-hydroxyapatite nanoparticle interaction for delivery of radiation and drugs. J Nanoparticle Res 2008;10(1):141-50
51. McLeod K, Anderson GI, Dutta NK, et al. Adsorption of bisphosphonate onto hydroxyapatite using a novel co-precipitation technique for bone growth enhancement. J Biomed Mater Res Part A 2006;79(2):271-81 (Pubitemid 44652026)
52. Fernandez E, Gil FJ, Ginebra MP, et al. Calcium phosphate bone cements for clinical applications. Part II: Precipitate formation during setting reactions. J Mater Sci: Mater Med 1999;10(3):177-83 (Pubitemid 29121945)
53. Bigi A, Panzavolta S, Rubini K. Setting mechanism of a biomimetic bone cement. Chem Mater 2004;16(19):3740-5 (Pubitemid 39369010)
54. Ginebra MP, Rilliard A, Fernndez E, et al. Mechanical and rheological improvement of a calcium phosphate cement by the addition of a polymeric drug. J Biomed Mater Res 2001;57(1):113-18 (Pubitemid 32661259)
55. Schnitzler V, Fayon F, Despas C, et al. Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: Critical influence of the drug introduction mode on the in vitro cement properties. Acta Biomaterialia 2010;doi:10.1016/j.actbio. 2010.09.017
56. Panzavolta S, Torricelli P, Bracci B, et al. Alendronate and pamidronate calcium phosphate bone cements: Setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem 2009;103(1):101-6
57. Giocondi JL, El-Dasher BS, Nancollas GH, Orme CA. Molecular mechanisms of crystallization impacting calcium phosphate cements. Philos Trans R Soc A: Math Phys Eng Sci 2010;368(1917):1937-61
58. Epstein H, Berger V, Levi I, et al. Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J Control Release 2007;117(3):322-32 (Pubitemid 46216576)
59. Cohen-Sela E, Chorny M, Koroukhov N, et al. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release 2009;133(2):90-5
60. Perugini P, Genta I, Conti B, et al. Long-term release of clodronate from biodegradable microspheres. AAPS PharmSciTech [electronic resource] 2001;2(3):E10 (Pubitemid 41086075)
61. Yaffe A, Herman A, Bahar H, Binderman I. Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats. J Periodontol 2003;74(7):1038-42 (Pubitemid 37038539)
62. Wiedenauer U, Bodmer D, Kissel T. Microencapsulation of hydrophilic drug substances using biodegradable polyesters. Part I: Evaluation of different techniques for the encapsulation of Pamidronate di-sodium salt. J Microencapsul 2003;20(4):509-24 (Pubitemid 36805897)
63. Weidenauer U, Bodmer D, Kissel T. Microencapsulation of hydrophilic drug substances using biodegradable polyesters. Part II: Implants allowing controlled drug release -A feasibility study using bisphosphonates. J Microencapsul 2004;21(2):137-49 (Pubitemid 38401094)
64. Shi X, Wang Y, Varshney RR, et al. In-vitro osteogenesis of synovium stem cells induced by controlled release of bisphosphate additives from microspherical mesoporous silica composite. Biomaterials 2009;30(23-24):3996- 4005
65. Billon-Chabaud A, Gouyette A, Merle C, Bouler JM. Development of bisphosphonates controlled delivery systems for bone implantation: Influence of the formulation and process used on in vitro release. J Mater Sci: Mater Med 2010;21(5):1599-604
66. Gautier H, Merle C, Auget JL, Daculsi G. Isostatic compression, a new process for incorporating vancomycin into biphasic calcium phosphate: Comparison with a classical method. Biomaterials 2000;21(3):243-9
67. Healey JH, Shannon F, Boland P, DiResta GR. PMMA to stabilize bone and deliver antineoplastic and antiresorptive agents. Clin Orthop Relat Res 2003;Oct(415 Suppl):S263-S275 (Pubitemid 37323345)
68. Horowitz SM, Algan SA, Purdon MA. Pharmacologic inhibition of particulate-induced bone resorption. J Biomedi Mater Res 1996;31(1):91-6
69. Lewis G, Janna S. Alendronate in bone cement: Fatigue life degraded by liquid, not by powder. Clin Orthop Relat Res 2006(445):233-8 (Pubitemid 44341350)
70. Sabokbar A, Fujikawa Y, Murray DW, Athanasou NA. Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption. Ann Rheum Dis 1998;57(10):614-18 (Pubitemid 28513140)
71. Rodriguez-Lorenzo LM, Fernandez M, Parra J, et al. Acrylic injectable and self-curing formulations for the local release of bisphosphonates in bone tissue. J Biomed Mater Res Part B Appl Biomater 2007;83(2):596-608 (Pubitemid 350005033)
72. Zenios M, Nokes L, Galasko CSB. Effect of a bisphosphonate, disodium pamidronate, on the quasi-static flexural properties of Palacos R acrylic bone cement. J Biomed Mater Res Part B Appl Biomater 2004;71(2):322-6 (Pubitemid 39463767)
73. Yu NYC, Ruys AJ, Zenios M, et al. Bisphosphonate-laden acrylic bone cement: Mechanical properties, elution performance, and in vivo activity. J Biomed Mater Res Part B Appl Biomater 2008;87(2):482-91
74. Varghese OP, Sun W, Hilborn J, Ossipov DA. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: A hydrogel linked prodrug approach. J Am Chem Soc 2009;131(25):8781-3 . The first report of tailored synthesis of hyaluronan-BP conjugate having crosslinkable functionality.
75. Doschak MR, Kucharski CM, Wright JEI, et al. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol Pharm 2009;6(2):634-40
76. Liu XM, Lee HT, Reinhardt RA, et al. Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity. J Control Release 2007;122(1):54-62 (Pubitemid 47284559)
77. Astrand J, Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res 2004;22(2):244-9 (Pubitemid 38155278)
78. Yaffe A, Binderman I, Breuer E, et al. Disposition of alendronate following local delivery in a rat jaw. J Periodontol 1999;70(8):893-5 (Pubitemid 29400114)
79. Tengvall P, Skoglund B, Askendal A, Aspenberg P. Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. Biomaterials 2004;25(11):2133-8 (Pubitemid 38102413)
80. Aya-Ay J, Athavale S, Morgan-Bagley S, et al. Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head. J Bone Miner Res 2007;22(1):93-100 (Pubitemid 46032601)
81. Greiner S, Kadow-Romacker A, Wildemann B, et al. Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro. J Biomed Mater Res Part A 2007;83(4):1184-91 (Pubitemid 350231781)
82. Cenni E, Granchi D, Avnet S, et al. Biocompatibility of poly(D,L-lactide-coglycolide) nanoparticles conjugated with alendronate. Biomaterials 2008;29(10):1400-11
83. Peter B, Pioletti DP, Laib S, et al. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone 2005;36(1):52-60 (Pubitemid 40128274)
84. Meraw SJ, Reeve CM, Wollan PC. Use of alendronate in peri-implant defect regeneration. J Periodontol 1999;70(2):151-8
85. Stadelmann VA, Gauthier O, Terrier A, et al. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater 2008;16:10-6
86. Verron E, Gauthier O, Janvier P, et al. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite. Biomaterials 2010;31(30):7776-84
87. Binderman I, Adut M, Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J Periodontol 2000;71(8):1236-40 (Pubitemid 30655955)
88. Yaffe A, Golomb G, Breuer E, Binderman I. The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. J Periodontol 2000;71(10):1607-12
89. Kaynak D, Meffert R, Gunhan M, et al. A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 2000;71(5):790-6 (Pubitemid 30483542)
90. Yaffe A, Iztkovich M, Earon Y, et al. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J Periodontol 1997;68(9):884-9 (Pubitemid 27411022)
91. Levin L, Bryson EC, Caplan D, Trope M. Effect of topical alendronate on root resorption of dried replanted dog teeth. Dental Traumatol 2001;17(3):120-6 (Pubitemid 33699239)
92. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62(22):6538-44 (Pubitemid 35364119)
93. Nagai T, Imai H, Honda S, Negi A. Antiangiogenic effects of bisphosphonates on laser-induced choroidal neovascularization in mice. Investig Ophthalmol Vis Sci 2007;48(12):5716-21 (Pubitemid 351260876)
94. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302(3):1055-61 (Pubitemid 34920226)
95. Lambrinoudaki I, Christodoulakos G, Botsis D. Bisphosphonates. Ann NY Acad Sci 2006;1092:397-402 (Pubitemid 47092356)
96. Denissen H, Van Beek E, Martinetti R, et al. Net-shaped hydroxyapatite implants for release of agents modulating periodontal-like tissues. J Periodontal Res 1997;32(1 PART 1):40-6 (Pubitemid 127520033)
97. Piattelli A, Scarano A, Mangano C. Clinical and histologic aspects of biphasic calcium phosphate ceramic (BCP) used in connection with implant placement. Biomaterials 1996;17(18):1767-70 (Pubitemid 26355419)
98. Yu H, Qin A. Could local delivery of bisphosphonates be a new therapeutic choice for hemangiomas? Med Hypotheses 2009;73(4):495-7
99. Pignatello R, Cenni E, Micieli D, et al. A novel biomaterial for osteotropic drug nanocarriers: Synthesis and biocompatibility evaluation of a PLGA-ALE conjugate. Nanomedicine 2009;4(2):161-75
100. Truong SV, Chang LC, Berger TG. Bisphosphonate-related osteonecrosis of the jaw presenting as a cutaneous dental sinus tract: A case report and review of the literature. J Am Acad Dermatology 2010;62(4):672-6